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LETTER TO THE EDITORS
Case Letter
Dear Editor,
Chemotherapy-induced alopecia: A novel observation
Chemotherapy-induced alopecia is a psychologically dis-
tressing consequence of some cancer treatment. Incidence
is estimated at 65% with ‘classic’ anticancer drugs and
14.7% with new targeted therapies.1 Hair-shaft shedding
can appear within 2 weeks (anagen efﬂuvium), or less
often, months after the beginning of therapy (telogen efﬂu-
vium). Although permanent alopecia has been reported in
up to 20% of cases, chemotherapy-induced alopecia is usu-
ally reversible, even if texture and colour persist.2,3
We describe a novel trichoscopic pattern of chemother-
apy-induced alopecia. We observed two patients with che-
motherapy-induced alopecia whose hair regrew ‘black and
white’ after three cycles of 5-ﬂuorouracil, epirubicin and
cyclophosphamide and 12 cycles of taxanes for breast can-
cer. Hairs that emerged from follicular ostia appeared
non-pigmented, but within a few millimetres of length they
became pigmented, appearing bicolored (white at the tips
and pigmented at the base; Figs 1,2).
Chemotherapy affects hair pigmentation with different
mechanisms. It causes oxidative damage to the hair follicle
pigmentary unit, and induces a complex melanocyte
response.4 Moreover, enzymatically determined intrafollic-
ular synthesis of eumelanin (black) and pheomelanin (red)
may also be affected.5
Figure 2 (a, b) Clinical and (c) trichoscopic images of the second patient: the hair shaft appears white at the tips and pigmented at the base.
Conﬂict of interest: none.
Figure 1 Trichoscopy of the ﬁrst patient shows several ‘black and white’ hairs.
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We hypothesize that our observation is the result of a
reactivation of follicular melanocytes that were damaged
but not destroyed. It is conceivable that this reﬂects the
end of a taxane-associated blockade of microtubules that
leads to a paralysis of melanosome transport.6 A further
possible mechanism could be the migration of amelanotic
melanocytes residing in the root sheath, which were
recalled and activated by morphogenetic signals generated
by the follicular niche. This last hypothesis is supported by
the fact that both patients had white hair prior to
chemotherapy. It is possible that recovery after chemother-
apy could activate senescent pigmentary units.
The phenomenon we observed is not exclusive to che-
motherapy-induced alopecia as white tips are a normal occur-
rence on nasal hairs and in regrowth after alopecia areata.
Chemotherapy-induced alopecia differs to alopecia areata,
which is characterized by the presence of vellus-like hair dur-
ing the recovering phase. These hairs are destined to complete
the hair-cycle, to fall out, and then to be replaced by pig-
mented terminal hair.7 Chemotherapy-induced alopecia, on
the other hand, does not necessarily need a whole hair cycle
to reestablish pigmentation.
A longer observation time is required to determine how
long these pigmentary modiﬁcations last and further studies
are necessary for a better understanding of this process.
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